drugset / Trial / NCT00003969

Geldanamycin Analogue in Treating Patients With Advanced Cancer

NCT00003969

Phase 1 Completed Cancer Research UK
Treatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase I trial is studying the side effects and best dose of a geldanamycin analogue in treating patients with advanced cancer.

Timeline

Start
1998-08
Primary completion
Completion
2007-01

Drugs

EvaluationDrugModalityDoseRoute
Subject tanespimycin Unknown 10 mg/m2 Intravenous
Subject tanespimycin Unknown 320 mg/m2 Intravenous
Subject tanespimycin Unknown 450 mg/m2 Intravenous